Advertisement
UK markets closed

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     

  • CRUDE OIL

    79.13
    -2.80 (-3.42%)
     

  • GOLD FUTURES

    2,330.20
    +27.30 (+1.19%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • Bitcoin GBP

    46,242.97
    -1,814.74 (-3.78%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

  • NASDAQ Composite

    15,605.48
    -52.34 (-0.33%)
     

  • UK FTSE All Share

    4,418.60
    -11.65 (-0.26%)
     
Money:

Family finances

Who is the breadwinner in your family and does it matter?

BRIEF-Morphosys, I-Mab Sign Agreement For Morphosys's Novel Immuno-Oncology Agent MOR210

Reuters

Nov 16 (Reuters) - MorphoSys AG:

* DGAP-NEWS: MORPHOSYS AND I-MAB SIGN STRATEGIC PARTNERING AGREEMENT FOR MORPHOSYS'S NOVEL IMMUNO-ONCOLOGY AGENT MOR210

* MORPHOSYS -UNDER TERMS OF AGREEMENT, I-MAB WILL EXERCISE ITS EXCLUSIVE LICENSE RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF MOR210 IN ITS TERRITORIES

* MORPHOSYS WILL RECEIVE AN UPFRONT PAYMENT OF $3.5 MILLION FROM I-MAB

* MORPHOSYS- I-MAB TO HAVE EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE MOR210 IN CHINA, HONG KONG, MACAO, TAIWAN, SOUTH KOREA Source text for Eikon: Further company coverage: